Aptose, CrystalGenomics in deal for multi-kinase inhibitor

CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to

Read the full 169 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE